TY - JOUR
TI - Survival among patients with relapsed/refractory diffuse large B cell
lymphoma treated with single-agent selinexor in the SADAL study
AU - Maerevoet, Marie
AU - Zijlstra, Josee M.
AU - Follows, George and
AU - Casasnovas, Rene-Olivier
AU - Vermaat, J. S. P.
AU - Kalakonda, Nagesh and
AU - Goy, Andre
AU - Choquet, Sylvain
AU - Van den Neste, Eric
AU - Hill, Brian
AU - and Thieblemont, Catherine
AU - Cavallo, Federica
AU - De la Cruz, Fatima
AU - and Kuruvilla, John
AU - Hamad, Nada
AU - Jaeger, Ulrich
AU - Caimi, Paolo
AU - and Gurion, Ronit
AU - Warzocha, Krzysztof
AU - Bakhshi, Sameer and
AU - Sancho, Juan-Manuel
AU - Schuster, Michael
AU - Egyed, Miklos
AU - Offner,
AU - Fritz
AU - Vassilakopoulos, Theodoros P.
AU - Samal, Priyanka
AU - Ku,
AU - Matthew
AU - Ma, Xiwen
AU - Corona, Kelly
AU - Chamoun, Kamal
AU - Shah,
AU - Jatin
AU - Shacham, Sharon
AU - Kauffman, Michael G.
AU - Canales, Miguel
JO - Journal of Hematology & Oncology
PY - 2021
VL - 14
TODO - 1
SP - null
PB - BMC
SN - 1756-8722
TODO - 10.1186/s13045-021-01122-1
TODO - Selinexor; Exportin-1; SINE compounds; DLBCL
TODO - Patients with RR DLBCL who have received >= 2 lines of therapy have
limited treatment options and an expected overall survival (OS) of < 6
months. The SADAL study evaluated single-agent oral selinexor in
patients with RR DLBCL and demonstrated an overall response rate (ORR)
of 29.1% with median duration of response (DOR) of 9.3 months. The
analyses described here evaluated a number of subpopulations in order to
understand how response correlates with survival outcomes in order to
identify patients who could most optimally benefit from selinexor
treatment. Median age was 67 years; 44.8% of patients were >= 70 years
of age. The median OS was 9.0 months (95% CI 6.2, 13.7) at a median
follow-up of 14.8 months. The median OS was not reached in patients with
a CR or PR, while patients who did not respond have a median OS of 4.9
months (p < 0.0001). Patients < 70 years had an OS of 11.1 months
compared with 7.8 months in patients >= 70 years. Among patients with or
without prior ASCT, the median OS was 10.9 and 7.8 months, respectively.
Among patients with disease refractory to the most recent DLBCL
treatment regimen, the median OS was 7.0 months compared with 11.1
months for disease not refractory to the most recent treatment. In a
patient population in which survival is expected to be < 6 months,
treatment with single-agent oral selinexor was associated with a median
survival of 9 months. Increased median OS observed in patients
responding to selinexor was consistent across subgroups regardless of
age, prior ASCT therapy, or refractory status. Randomized studies of
selinexor in combination with a variety of other anti-DLBCL agents are
planned.
ER -